Clearside Biomedical (NASDAQ:CLSD) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies that leverage its proprietary suprachoroidal space (SCS) drug delivery platform to treat eye diseases. The company’s SCS Microinjector™ enables targeted administration of small molecule and biologic therapies directly to the back of the eye, offering potential benefits in efficacy and safety over conventional intravitreal or systemic approaches. Clearside’s research and development efforts are concentrated on retinal and choroidal disorders that represent significant unmet medical needs, including macular edema, age-related macular degeneration and diabetic retinopathy.
The company’s first approved product, Xipere® (triamcinolone acetonide injectable suspension), is designed for suprachoroidal administration to address macular edema associated with uveitis. In addition to this commercial offering, Clearside maintains a robust pipeline of product candidates, including CLS-AX (axitinib suprachoroidal injectable suspension) for the treatment of neovascular age-related macular degeneration and CLS-301, an anti-VEGF therapy in preclinical development for diabetic macular edema. These programs exemplify the versatility of Clearside’s delivery technology in accommodating both small molecules and larger biologics within the same targeted anatomical space.
Founded in 2009 and headquartered in Alpharetta, Georgia, Clearside has built strategic collaborations and licensing agreements to advance its technology into new markets. The company conducts clinical trials across the United States and in select international locations, fostering partnerships with contract research organizations and academic medical centers. Clearside’s intellectual property portfolio includes multiple issued patents covering the SCS delivery method, as well as key formulation and device innovations that underpin its therapeutic platform.
Under the leadership of Chief Executive Officer Jeff S. Boyer and supported by a management team with deep expertise in ophthalmology, pharmacology and medical device development, Clearside is positioned to address a broad spectrum of posterior segment diseases. The company’s strategic plan emphasizes advancing late-stage clinical candidates, expanding global regulatory submissions and fostering commercial readiness to bring next-generation ocular therapies to physicians and patients worldwide.
